Immobilized hemeprotein scavengers for the treatment of carbon monoxide poisoning
Immobilizing recombinant hemeproteins on agarose resin in dialysis cartridges addresses the limitations of intravenous treatments by safely and effectively removing carbon monoxide from the blood, reducing toxicity risks and enhancing treatment efficacy.
WO2026156291A1PCT designated stage Publication Date: 2026-07-23UNIV OF PITTSBURGH OF THE COMMONWEALTH SYST OF HIGHER EDUCATION +1
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- UNIV OF PITTSBURGH OF THE COMMONWEALTH SYST OF HIGHER EDUCATION
- Filing Date
- 2026-01-16
- Publication Date
- 2026-07-23
Smart Images
Figure US2026011649_23072026_PF_FP_ABST
Abstract
Compositions that include recombinant globin proteins, such as human recombinant neuroglobin or cytoglobin or recombinant regulator of carbon monoxide metabolism (RcoM) protein, that bind carbon monoxide with high affinity are described. The recombinant hemeproteins are immobilized on a solid support, such as an agarose resin. The recombinant hemeproteins can be cross-linked to the agarose resin using N-hydroxysuccinimide (NHS). The immobilized hemeproteins can be incorporated into dialysis cartridges and extracorporeal systems to filter CO from the blood of a subject with CO poisoning. Non-immobilized hemeproteins for use in a standard dialysis system are also described.
Need to check novelty before this filing date? Find Prior Art